How do biosimilars differ from generics, and what are key considerations for their regulatory approval and interchangeability?

• A. Biosimilars are identical to reference biologics with no differences.
• B. Biosimilars are less similar than generics and require no comparability data.
• C. Biosimilars are highly similar to reference biologics with no clinically meaningful differences; regulatory focus on extensive comparability; interchangeability requires additional evidence of no switching risk.
• D. Biosimilars are synthetic chemicals; generics are proteins.

Answer: (C)

Biosimilars are designed to be highly similar to a reference biologic, but because biologics are large, complex proteins produced in living systems, they cannot be exact copies. Minor differences in manufacturing can occur, yet these differences must not lead to meaningful changes in safety, efficacy, or immunogenicity, which is why regulators require a rigorous comparability program.

The regulatory focus is on extensive data showing similarity across multiple dimensions: detailed analytical characterization of structure and function; nonclinical and clinical studies that confirm comparable pharmacokinetics/pharmacodynamics, efficacy, and safety; and assessments of immunogenicity. Only if no clinically meaningful differences are demonstrated is a product considered a biosimilar.

Interchangeability is an additional designation in some regions (not automatically granted). It requires evidence that switching between the biosimilar and the reference product does not increase risk or reduce efficacy, often demonstrated through switching studies and robust immunogenicity data; even when a product is biosimilar, it may not be labeled interchangeable.

Generics, by contrast, are copies of small-molecule drugs and are typically identical in active ingredient with demonstrated bioequivalence, which makes the regulatory path simpler and usually does not involve extensive immunogenicity or comparability data.